US11246758B2 - Open-cavity, reduced-pressure treatment devices and systems - Google Patents

Abstract

An open-cavity, reduced-pressure treatment device and system for treating a cavity in a patient's body, such as an abdominal cavity, is presented. In one instance, an open-cavity, reduced-pressure treatment device includes a plurality of encapsulated leg members, each having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion, and a central connection member fluidly coupled to the plurality of encapsulated leg members. The central connection member has a connection manifold member. The open-cavity, reduced-pressure treatment devices, systems, and methods allow for, among other things, removal of fluids.

Description

RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/018,594, filed Feb. 8, 2016, entitled “Open-Cavity, Reduced-Pressure Treatment Devices and Systems,” which is a continuation of U.S. patent application Ser. No. 13/458,006, now U.S. Pat. No. 9,289,327, filed Apr. 27, 2012, entitled “Open-Cavity, Reduced-Pressure Treatment Devices and Systems,” which is a divisional of U.S. patent application Ser. No. 12/467,064, now U.S. Pat. No. 8,192,409, filed May 15, 2009, entitled “Open-Cavity, Reduced-Pressure Treatment Devices and Systems,” which claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 61/109,410, entitled “Reduced-Pressure, Wound-Closure System and Method,” filed Oct. 29, 2008; U.S. Provisional Patent Application Ser. No. 61/109,486, entitled “Reduced-Pressure, Abdominal Treatment System and Method,” filed Oct. 29, 2008; U.S. Provisional Patent Application Ser. No. 61/109,390, entitled “Open-Cavity, Reduced-Pressure Wound Dressing and System,” filed Oct. 29, 2008; and U.S. Provisional Patent Application Ser. No. 61/109,448, entitled “Reduced-Pressure, Deep-Tissue Closure System and Method,” filed Oct. 29, 2008. Each of the above-referenced applications are incorporated herein by reference for all purposes.

BACKGROUND

The present invention relates generally to medical treatment systems and, more particularly, to open-cavity, reduced-pressure treatment devices and systems.

Whether the etiology of a wound, or damaged area of tissue, is trauma, surgery, or another cause, proper care of the wound, or wounds, is important to the outcome. Unique challenges exist when the wound involves locations that require reentry, for example, the peritoneal cavity and more generally the abdominal cavity. Often times when surgery or trauma involves the abdominal cavity, establishing a wound management system that facilitates reentry, allows for better and easier care, and helps to address such things as peritonitis, abdominal compartment syndrome, and infections that might inhibit final healing of the wound and the internal organs. In providing such care, it may be desirable to remove unwanted fluids from the cavity, help approximate the fascia and other tissues, and finally to help provide a closing force on the wound itself at the level of the epidermis.

Currently, an abdominal opening on the epidermis may be closed using sutures, staples, clips, and other mechanical devices to allow the skin, or epidermis, to be held and pulled. Such devices cause wounds in and of themselves. Moreover, without more, if edema occurs, tremendous pressure may be placed on the closure device with potential harm resulting. For example, if pressure rises due to edema, sutures may tear out.

With respect to an overall system for allowing reentry into the abdominal cavity, a number of techniques have been developed. One approach is to place towels down into the cavity and then use clips, such as hemostats, to close the skin over the towels. While simple and fast, the results appear to have been regarded as suboptimal. Another approach is the “Bogota bag.” With this approach, a bag is sutured into place to cover the open abdomen. Still another approach, sometimes called a “vac pack,” has been to pack towels in the wound and then place a drain into the abdomen and cover the abdomen with a drape. Finally, a reduced pressure approach has been used. Such an approach is shown in U.S. Pat. No. 7,381,859 to Hunt et al. and assigned to KCl Licensing, Inc. of San Antonio, Tex. U.S. Pat. No. 7,381,859 is incorporated herein by reference for all purposes.

In addition to accessing the cavity for reentry, it may be desirable to remove fluids from the cavity. It may also be desirable to provide reduced-pressure therapy to the tissue or wound, including wounds that may be within the abdominal cavity. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) may provide a number of benefits, including faster healing and increased formulation of granulation tissue.

It would be desirable to provide a system and method that could remove excess fluids from an abdominal cavity, protect the interior of the abdominal cavity by providing a non-adherent barrier, and deliver reduced pressure. Further, it would be desirable to provide a system that can be readily placed in various locations in the abdominal cavity, such as paracolic gutters, is quickly installed, and that easily accommodates different size areas.

SUMMARY

Shortcomings with existing dressings and systems for open cavities, such as abdominal cavities, are addressed by the systems, apparatus, and methods of the illustrative embodiments described herein. According to one illustrative embodiment, a reduced-pressure treatment system for providing reduced-pressure treatment within a body cavity of a patient may include a treatment device having a plurality of encapsulated leg members, each encapsulated leg member having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion. The treatment device also includes a central connection member having a connection manifold member and wherein each leg manifold member is in fluid communication with the connection manifold member. The central connection member has a first side and a second, inward-facing side. The reduced-pressure treatment system further includes a manifold for disposing proximate the first side of the central connection member and operable to distribute reduced pressure to the central connection member; a sealing member for disposing on a portion of the patient's epidermis and operable to form a pneumatic seal over the body cavity; a reduced-pressure conduit; and a reduced-pressure source for producing reduced pressure. The reduced-pressure source is fluidly coupled to the reduced-pressure delivery conduit, which is fluidly coupled to a reduced-pressure interface.

According to another illustrative embodiment, an open-cavity, reduced-pressure treatment device for treating a tissue site in a body cavity includes a plurality of encapsulated leg members, each encapsulated leg member having an interior portion with a leg manifold member. The plurality of encapsulated leg members are formed with fenestrations operable to allow fluid flow into the interior portion. The open-cavity, reduced-pressure treatment device also includes a central connection member, which has a connection manifold member. The plurality of encapsulated leg members are in fluid communication with the connection manifold member.

According to another illustrative embodiment, a method of manufacturing a reduced-pressure treatment device for use in a body cavity of a patient includes the steps of: forming a plurality of encapsulated leg members, each encapsulated leg member having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion. The method of manufacturing a reduced-pressure treatment device further includes forming a central connection member having a connection manifold member and fluidly coupling the central connection member to the plurality of encapsulated legs, wherein each leg manifold member is in fluid communication with the connection manifold member. The illustrative method may also include placing visual indicia on the non-adherent drape that indicates various sizes that might be cut.

According to another illustrative embodiment, a method of providing reduced-pressure treatment in an abdominal cavity of a patient may include the steps of: disposing a treatment device into the abdominal cavity, wherein the treatment device has a plurality of encapsulated leg members, each encapsulated leg member having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion, and a central connection member, wherein the central connection member has a connection manifold member and wherein each leg manifold member is in fluid communication with the connection manifold member. The central connection member has a first side and a second, inward-facing side. The method further includes placing at least one of the plurality of encapsulated leg members proximate a paracolic gutter in the abdominal cavity; disposing a manifold proximate the first side of the central connection member; placing a sealing member on a portion of the patient's epidermis to form a pneumatic seal over the body cavity; coupling a reduced-pressure interface to the sealing member; and coupling a reduced-pressure conduit to the reduced-pressure interface to deliver reduced pressure to the manifold. The illustrative method may further include the step of sizing the treatment device before disposing the treatment device into the body cavity.

Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic diagram, with a portion in cross section, of an illustrative embodiment of an open-cavity, reduced-pressure treatment device and system;

FIG. 1B is a schematic cross section of a portion of the treatment device ofFIG. 1A;

FIG. 1C is a schematic cross section of a portion of the treatment device ofFIG. 1A taken alongline1C-1C;

FIG. 1D is a schematic cross section of a portion of the system ofFIG. 1A;

FIG. 2 is a schematic, perspective view of the illustrative embodiment of an open-cavity, reduced-pressure treatment device ofFIGS. 1A-1D;

FIG. 3A is a schematic, plan view of another illustrative embodiment of an open-cavity, reduced-pressure treatment device;

FIG. 3B is a schematic, plan view of a portion of the treatment device ofFIG. 3A;

FIG. 3C is a schematic cross section of a portion of the treatment device ofFIG. 3B taken alongline3C-3C;

FIG. 4 is schematic, perspective view of another illustrative embodiment of an open-cavity, reduced-pressure treatment device; and

FIG. 5 is a schematic, plan view of another illustrative embodiment of an open-cavity, reduced-pressure treatment device.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.

Referring toFIGS. 1A-1D, an illustrative embodiment of an open-cavity, reduced-pressure system100 and atreatment device102 is presented. The open-cavity reduced-pressure system100 and thetreatment device102 are for treating atissue site104 of a patient. Thetissue site104 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. In this illustrative embodiment, thetissue site104 includes tissue in a body cavity, and in particular the abdominal cavity, and includes the abdominal contents or tissue that is proximate the abdominal cavity. Treatment of thetissue site104 may include removal of fluids, e.g., ascites, protection of the abdominal cavity, or reduced-pressure therapy. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity.

As shown, thetreatment device102 is disposed within the abdominal cavity of the patient to treat thetissue site104. Thetreatment device102 includes a plurality of encapsulatedleg members106 that are supported by the abdominal contents, which make up a surface on which the plurality ofleg members106 are placed. One or more of the plurality of encapsulatedleg members106 may be placed in or proximate to a firstparacolic gutter108, and one or more of the plurality of encapsulatedleg members106 may be placed in or proximate to a secondparacolic gutter110. The plurality of encapsulatedleg members106 is coupled to acentral connection member112, and there is fluid communication between the plurality of encapsulatedleg members106 and thecentral connection member112. The plurality of encapsulatedleg members106 and/or thecentral connection member112 may be formed withfenestrations114,116,118,120 that allow fluids in the abdominal cavity to pass through. Thefenestrations114,116,118,120 may take any shape, e.g., circular apertures, rectangular openings, polygons, etc., but are presented in this illustrative embodiment as slits, or linear cuts. One or more fenestrations114,116,118,120 might be omitted in alternative embodiments.

A manifold122, or manifold pad, distributes reduced pressure to thetreatment device102. A sealingmember124 provides a pneumatic seal over body-cavity opening126. One or more skin closure devices may be placed on a patient'sepidermis134. Reduced pressure is delivered to the manifold122 through a reduced-pressure interface128, which is coupled to a reduced-pressure delivery conduit130. A reduced-pressure source132 delivers reduced pressure to the reduced-pressure delivery conduit130.

The reduced pressure may be applied to thetissue site104 to help promote removal of ascites, exudates, or other fluids from thetissue site104. In some instances, reduced pressure may be applied to stimulate the growth of additional tissue. In some instances, only fluid removal may be desired. In the case of a wound at thetissue site104, the growth of granulation tissue, removal of exudates, or removal of bacteria may help to promote healing of the wound. In the situation of a non-wounded or non-defective tissue, reduced pressure may be used in some instances to promote the growth of tissue that may be harvested and transplanted to another tissue site. As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Reduced pressure may initially generate fluid flow in the manifold122, the reduced-pressure conduit130, and proximate thetissue site104. As the hydrostatic pressure around thetissue site104 approaches the desired reduced pressure, the flow may subside, and the reduced pressure may be maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures.

The manifold122 is proximate thecentral connection member112. The manifold122 may take many forms. The term “manifold” as used herein generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from thetissue site104. The manifold122 typically includes a plurality of flow channels or pathways that distribute the fluids provided to and removed from thetissue site104 around themanifold122 and through thecentral connection member112. In one illustrative embodiment, the flow channels or pathways are interconnected to improve distribution of fluids provided or removed from thetissue site104. The manifold122 may be a biocompatible material that is capable of being placed in contact with thetissue site104 and distributing reduced pressure to thetissue site104. Examples ofmanifold122 may include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam, such as open-cell foam, porous tissue collections, liquids, gels and foams that include or cure to include flow channels. The manifold122 may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. In one embodiment, the manifold122 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam, such as a GranuFoam® material manufactured by Kinetic Concepts, Incorporated of San Antonio, Tex. Other embodiments might include “closed cells.” These closed-cell portions of the manifold may contain a plurality of cells, the majority of which are not fluidly connected to adjacent cells. The closed cells may be selectively disposed in the manifold122 to prevent transmission of fluids through perimeter surfaces of themanifold122. In some situations, the manifold122 may also be used to distribute fluids such as medications, antibacterials, growth factors, and various solutions to thetissue site104. Other layers may be included in or on the manifold122, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.

The sealingmember124 is placed over the body-cavity opening126 and provides a pneumatic seal adequate for the open-cavity, reduced-pressure system100 to hold a reduced pressure at thetissue site104. The sealingmember124 may be a cover that is used to secure the manifold122 on thecentral connection member112. The sealingmember124 may be impermeable or semi-permeable. The sealingmember124 is capable of maintaining reduced pressure at thetissue site104 after installation of the sealingmember124 over the body-cavity opening126. The sealingmember124 may be a flexible over-drape or film formed from a silicone-based compound, acrylic, hydrogel or hydrogel-forming material, or any other biocompatible material that includes the impermeability or permeability characteristics as desired for applying reduced pressure to thetissue site104.

The sealingmember124 may further include an attachment means131 to secure the sealingmember124 to the patient'sepidermis134. The attachment means131 may take many forms; for example, anadhesive layer136 may be positioned along a perimeter of the sealingmember124 or any portion of the sealingmember124 to provide, directly or indirectly, the pneumatic seal with the patient'sepidermis134. Theadhesive layer136 might also be pre-applied to the sealingmember124 and covered with a releasable backing, or member (not shown), that is removed at the time of application.

The reduced-pressure interface128 may be, as one example, a port orconnector138, which permits the passage of fluid from the manifold122 to the reduced-pressure delivery conduit130 and vice versa. For example, fluid collected from thetissue site104 using themanifold122 and thetreatment device102 may enter the reduced-pressure delivery conduit130 via theconnector138. In another embodiment, the open-cavity, reduced-pressure system100 may omit theconnector138 and the reduced-pressure delivery conduit130 may be inserted directly into the sealingmember124 and into themanifold122. The reduced-pressure delivery conduit130 may be a medical conduit or tubing or any other means for transportating a reduced pressure and fluid. The reduced-pressure delivery conduit130 may be a multi-lumen member for readily delivering reduced pressure and removing fluids. In one embodiment, the reduced-pressure delivery conduit130 is a two-lumen conduit with one lumen for reduced pressure and liquid transport and one lumen for communicating pressure to a pressure sensor.

Reduced pressure is generated and supplied to the reduced-pressure delivery conduit130 by the reduced-pressure source132. A wide range of reduced pressures may be generated or supplied by the reduced-pressure source132. In one embodiment, the range may include the range −50 to −300 mm Hg and in another embodiment, the range may include −100 mm Hg to −200 mm Hg. In one illustrative embodiment, the reduced-pressure source132 includes preset selectors for −100 mm Hg, −125 mm Hg, and −150 mm Hg. The reduced-pressure source132 may also include a number of alarms, such as a blockage alarm, a leakage alarm, or a battery-low alarm. The reduced-pressure source132 could be a portable source, wall source, or other unit for abdominal cavities. The reduced-pressure source132 may selectively deliver a constant pressure, varied pressure, intermittent pressure, or continuous pressure. The fluid removed from the cavity through the reduced-pressure delivery conduit130 could be as much as 5 L or more per day.

A number of different devices, e.g.,device140, may be added to amedial portion142 of the reduced-pressure delivery conduit130. For example, thedevice140 might be a fluid reservoir, or canister collection member, a pressure-feedback device, a volume detection system, a blood detection system, an infection detection system, a filter, a port with a filter, a flow monitoring system, a temperature monitoring system, etc.Multiple devices140 might be included. Some of these devices, e.g., the fluid collection member, may be formed integral to the reduced-pressure source132. For example, a reduced-pressure port144 on the reduced-pressure source132 may include a filter member (not shown) that includes one or more filters and may include a hydrophobic filter that prevents liquid from entering an interior space of the reduced-pressure source132.

Referring now to FIGURES,1C,1D and2, thetreatment device102 can include anon-adherent drape148. Thenon-adherent drape148 may be formed of a non-adherent material that inhibits tissue adhesion to thenon-adherent drape148. In one embodiment, thenon-adherent drape148 is formed from a breathable polyurethane film. Thenon-adherent drape148 can include a plurality of openings, apertures, orfenestrations150. The fenestrations can take a variety of shapes, such as circular openings, rectangular openings, polygon-shaped openings, etc., but are shown inFIG. 2 as slits, or linear cuts. Depending on the particular application ofdevice102, the desired fluid flow and/or pressure delivery, or other system parameters, the fenestrations can different sizes.

Thetreatment device102 includes thecentral connection member112 to which the plurality of encapsulatedleg members106 are coupled. Thecentral connection member112 includes amanifold member154 that is encapsulated by a firstconnection encapsulation member186 and a secondconnection encapsulation member192. However, a portion of the central connection member can fluidly couple atleg coupling areas152 to permit fluid communication between thecentral connection member112 and the plurality of encapsulatedleg members106. The first and second connection encapsulation members may be a defined by a single piece of material or, as illustrated, more than one sheet of material.

Thecentral connection member112, as discussed above, can fluidly communicate withmanifold122. In one aspect, fenestrations118, similar to the fenestrations discussed above can permit fluid communication. Additionally, or alternatively, a portion or portions of the first connection encapsulation member can be exposed tomanifold112.

Referring again toFIGS. 1A-1D, each of the plurality of encapsulatedleg members106 can include aleg manifold member160, which may be a single manifold member that runs between theleg modules156 and/orcentral connection member112, or individual manifold components. Theleg manifold member160 is disposed within aninterior portion162 of each of the encapsulatedleg members106. Eachleg manifold member160 has afirst side164 and a second, inward-facing (patient-facing)side166.

In one embodiment, one or more of the plurality ofleg manifold members160 can have different material properties or structures. For example, different flow rates may be desired in different encapsulatedleg members106. In one aspect, different manifold materials or manifold properties, different manifold sizes, manifold compression, the use flow restricting material structures, and/or or valves can provide different flow rates of fluid through the encapsulated leg members and/or central connection member.

In one aspect, a firstleg encapsulating member168, which can be formed withfenestrations114, is disposed on thefirst side164 of theleg manifold member160. A secondleg encapsulating member170, which can includefenestrations116, is disposed on the second, inward-facingside166 of theleg manifold member160. The secondleg encapsulating member170 may be a portion of thenon-adherent drape148. In one embodiment, the encapsulatedleg members106 can be mated with one another, for example, viadrape148. Alternatively, the leg members can be independently movable with respect to one another with the exception of their proximal end adjacent to thecentral connection member112. For example, the leg members need not be connected to one another. In another embodiment, a portion of the material connecting the leg members, e.g., thenon-adherent drape148 betweenadjacent leg members106, is expandable (e.g., a stretchable, flexible, deformable, and/or elastic material) and permits movement ofindividual leg members106 with respect to one another.

As shown in the longitudinal cross section ofFIG. 1B byarrows172, fluid can flow fromleg modules156 towards thecentral connection member112. As shown byarrows174, the fluid is able to enterfenestrations114 and116 and flow into theleg manifold member160 and then flow toward thecentral connection member112 as represented byarrows172.

In plan view, the encapsulatedleg members106 may take a number of different shapes, such as elongate shapes, rectangular, elliptical, etc. In one aspect, the encapsulatedleg members106 may includeleg modules156.Adjacent leg modules156 are fluidly coupled to each other and have amanipulation zone158 between them. In one aspect, the manipulation zone includes a weakened or perforated area to facilitate sizing of the device. For example, a clinician can cut through a leg module to size the device. By pulling on the partially cut leg module the manifold can be torn away at the next manipulation zone. In one aspect, the recessed shape of themanipulation zone158 can inhibit accidental removal of additional leg modules. Additionally, or alternatively, the outer portion of the leg modules can be fixed to the device to inhibit unwanted manifold removal.

The encapsulatedleg members106 may also have various dimensions. If the longer dimension, e.g., lengthwise or longitudinal dimension, of the encapsulatedleg106 is_L1and the width is_W1, then the aspect ratio is given by_L1/_W1. The aspect ratio may be 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0 or any number in between. Moreover, other aspect ratios are possible. Generally, the width_W1of the encapsulated leg member will be greater than a width_W2of thecentral connection member112, i.e.,_W2>_W1. For example, in one illustrative embodiment, the encapsulatedleg members106 are approximately 270 mm long, 60 mm wide (_W1), and 10 mm thick, and the central connection member has a width parallel to the first width (_W1) of about 130 mm (_W2). Thus, in that illustrative example, the aspect ratio of the encapsulatedleg106 is approximately (270/60) or 4.5. In this same illustrative embodiment, themanipulation zones158 have a width of about 10 mm.

Referring toFIG. 1C, a lateral cross section of a portion of the encapsulatedleg member106 is presented. As before, it can be seen that thefirst side164 of theleg manifold member160 is covered with the firstleg encapsulating member168, and that the second, inward-facingside166 of theleg manifold member160 is covered by the secondleg encapsulating member170, which in this instance is a portion of thenon-adherent drape148. Thus, in this illustrative embodiment, thefenestrations116 may be some of the plurality offenestrations150 in thenon-adherent drape148. In this illustrative embodiment, aperipheral edges176 of theleg manifold member160 are also covered by a portion of the firstleg encapsulating member168. Theperipheral edges176 include a firstlateral edge177 and a secondlateral edge179. The firstleg encapsulating member168 covers thefirst side164 and theperipheral edges176 and extends onto afirst surface178 of thenon-adherent drape148 andforms extensions180. Theextensions180 have been coupled to the secondleg encapsulating member170 bywelds182. The firstleg encapsulating member168 may, however, be coupled to the secondleg encapsulating member170 using any known technique, including welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.

Referring again toFIG. 1D andFIG. 2, thecentral connection member112 includes theconnection manifold member154 that is encapsulated within the firstconnection encapsulation member186, which hasfenestrations118. The firstconnection encapsulation member186 is disposed on afirst side188 of theconnection manifold member154. The secondconnection encapsulation member192 is disposed on a second, inward-facingside190 of theconnection manifold member154. The secondconnection encapsulation member192 is formed withfenestrations120. The firstconnection encapsulation member186 has a peripheral zone or edge194 as shown inFIG. 2. In a similar fashion, the secondconnection encapsulation member192 has a peripheral zone or edge (not explicitly shown) that lines up with theperipheral edge194. Theperipheral edge194 of the firstconnection encapsulation member186 is coupled to peripheral edge of the secondconnection encapsulation member192, except at theleg coupling areas152 in order to allow fluid within the plurality of encapsulatedleg members106 to flow into theconnection manifold member154 as suggested byarrows196 inFIG. 1D. Fluid may also enter directly into theconnection manifold member154 by flowing throughfenestrations120 as suggested byarrows198. The manifold122 is disposed proximate to the firstconnection encapsulation member186, and when a reduced pressure is applied to the manifold122, the reduced pressure causes fluid to flow from theconnection manifold member154 throughfenestrations118 and into the manifold122 as suggested byarrows200. The fluid continues to flow in the direction of the reduced-pressure interface128 through which the fluid is removed to the reduced-pressure delivery conduit130.

Referring toFIGS. 1A-1D and 2, in operation, the illustrative open-cavity, reduced-pressure system100 may be used by first sizing thetreatment device102 as will be explained further below in connection withFIG. 3A. Thenon-adherent drape148 with the plurality of encapsulatedleg members106 is disposed within the abdominal cavity through the body-cavity opening126 and is distributed against the abdominal contents; this may include placing at least one encapsulatedleg member106 in or proximate the firstparacolic gutter108, the secondparacolic gutter110, or behind the liver, etc. Once thetreatment device102 has been distributed, the manifold122 is placed adjacent afirst side184 of the firstconnection encapsulation member186. The sealingmember124 may then be applied over the body-cavity opening126 to provide a pneumatic seal over the body-cavity opening126.

In addition to the sealingmember124, the body-cavity opening126 may be further closed or reinforced using mechanical closing means, e.g., staples, or using a reduced-pressure closure system. The sealingmember124 may be applied in a number of ways, but according to one illustrative embodiment, the releasable backing member that is on theadhesive layer136 of the sealingmember124 is removed and then the sealingmember124 is placed against the patient'sepidermis134 about the body-cavity opening126. The reduced-pressure interface128, such asport138, is then attached to the sealingmember124 such that reduced pressure can be delivered by theinterface128, through the sealingmember124, and to themanifold122. The reduced-pressure delivery conduit130 is fluidly coupled to the reduced-pressure interface128 and to the reduced-pressure port144 on the reduced-pressure source132.

The reduced-pressure source132 is activated and thereby provides reduced pressure into the reduced-pressure delivery conduit130, which delivers the reduced pressure to the reduced-pressure interface128 and into themanifold122. The manifold122 distributes the reduced pressure and draws fluid throughfenestrations118 from theconnection manifold member154. Theconnection manifold member154 draws fluid from the abdominal cavity throughfenestrations120 and pulls fluid from the plurality of encapsulatedleg members106 as suggested byarrows196. Fluid from the abdominal cavity flows into the plurality of encapsulatedleg members106 throughfenestrations114 on the firstleg encapsulating member168 and throughfenestrations116 on the secondleg encapsulating member170 and then flows through the leg as suggested byarrows172 towards theconnection manifold member154. The fluid then flows through the manifold122, the reduced-pressure interface128, and into the reduced-pressure delivery conduit130.

Referring now toFIGS. 3A-3C, another illustrative embodiment of an open-cavity, reduced-pressure treatment device302 is presented. The open-cavity, reduced-pressure treatment device302 is analogous in most respects to thetreatment device102 ofFIGS. 1A-1D. The open-cavity, reduced-pressure treatment device302 has anon-adherent drape304, a plurality of encapsulatedleg members306, and acentral connection member308. In this particular illustrative embodiment, thenon-adherent drape304 is formed generally with an oval or arcuate shape. Thenon-adherent drape304 is formed with a plurality offenestrations305. Thenon-adherent drape304 forms the second leg encapsulating member (see by analogy secondleg encapsulating member170 inFIG. 1B) and the second connection encapsulation member (see byanalogy192 inFIG. 1D). As such, the plurality offenestrations305 serves as flow channels for the plurality of encapsulatedleg members306 and thecentral connection member308 on the second, inward-facing side. Thenon-adherent drape304 could also be used on the first side of the plurality of encapsulatedleg members306 and thecentral connection member308.

Each of the encapsulatedleg members306 may be formed with a plurality ofleg modules310 withmanipulation zones312 between the plurality ofleg modules310. As with themanipulation zone158 inFIGS. 1A-D, themanipulation zones312 facilitate movement of the plurality of encapsulatedleg members306 within the body cavity and provide an easier location at which to cut the plurality of encapsulatedleg members306 when the open-cavity, reduced-pressure treatment device302 is being sized for a particular application. In this regard,visual indicia314 may be added on thenon-adherent drape304 to help the healthcare provider know where to cut thenon-adherent drape304 for different sizes of application within the cavity. Thevisual indicia314 may comprise cut lines, or graduations, that preferably run through themanipulation zones312. Themanipulation zones312 provide a convenient and easy location for cutting the open-cavity, reduced-pressure treatment device302.

Referring toFIG. 3C, a lateral cross section of a portion of an encapsulatedleg member306 is presented. The plurality of encapsulatedleg members306 are formed with aleg manifold member318 having afirst side320 and a second, inward-facing (patient-facing)side322. A firstleg encapsulating member324 covers thefirst side320 of theleg manifold member318 and covers a lateral zone or edge326 of theleg manifold member318. The second, inward-facingside322 of theleg manifold member318 is covered by a secondleg encapsulating member328, which in this embodiment is a portion of thenon-adherent drape304. The firstleg encapsulating member324 is coupled to the secondleg encapsulating member328 by any means known in the art, such as by welding (e.g., ultrasonic or RF), bonding, adhesives, cements, etc. In this illustrative embodiment, the firstleg encapsulating member324 and the secondleg encapsulating member328 are coupled by aweld330. Referring toFIG. 3B, theweld330 is shown along the perimeter of the plurality ofleg modules310.

Referring again toFIG. 3A, thecentral connection member308 is formed analogously to thecentral connection member112 inFIG. 2. A firstconnection encapsulation member334 and a second connection encapsulation member of thecentral connection member308 are coupled along aperipheral edge332 using aweld333 or another coupling technique, such as those previously mentioned. Theperipheral edge332 is not sealed, however, proximate each of the encapsulatedleg members306 in order to provide a channel for fluid to flow from the plurality of encapsulatedleg members306 into thecentral connection member308.

According to one illustrative approach to constructing the open-cavity, reduced-pressure treatment device302, thenon-adherent drape304, which is already formed with the plurality offenestrations305 and that hasvisual indicia314 is provided. Theleg manifold member318 is disposed adjacent thenon-adherent drape304. Thecentral connection manifold308 is disposed adjacent to theleg manifold member318 or may be formed integral withleg manifold member318. The firstconnection encapsulation member334 is placed on thecentral connection member308, and the firstleg encapsulating member324 is placed over theleg manifold member318. The firstconnection encapsulation member334 and the firstleg encapsulating member324 may be formed from an integral sheet. Next, thewelds330 and333 are applied.

In an alternative embodiment for manufacturing an open-cavity, reduced-pressure treatment device, a firstnon-adherent drape304, which includes fenestrations, may be provided and theleg manifold member318 and thecentral connection manifold308 disposed on the firstnon-adherent drape304. A second non-adherent drape, which has fenestrations, is placed over the firstnon-adherent drape304, theleg manifold member318, and thecentral connection manifold308. Next, a plurality of welds (e.g., thermal or RF or another coupling techniques used) are made, such as with thewelds330. The firstnon-adherent drape304 and the second non-adherent drape may be cut to size before or after assembly. By using two drapes, the firstnon-adherent drape304 and the second non-adherent drape may provide better distribution of reduced pressure and may ease the manufacturing process.

The fenestrations may be formed before or after assembly. The perimeter of the firstnon-adherent drape304 and the second non-adherent drape may be welded. Other points may be welded between the drapes to form a single unit. In another alternative embodiment, the drapes may initially be placed and welded without fenestrations, and then fenestrations added to the drapes so that the fenestrations align. The fenestrations might also be formed using an electrical member that cuts and seals at the same time to form aligned, “button hole” fenestrations through the two drapes.

Referring now toFIG. 4, another illustrative embodiment of an open-cavity, reduced-pressure treatment device402 is presented. The open-cavity, reduced-pressure treatment device402 is similar to thetreatment device102 shown inFIG. 2, and to indicate analogous parts, reference numerals have been indexed by 300. The open-cavity, reduced-pressure treatment device402 differs primarily in that afluid delivery subsystem445 is included. A plurality of encapsulatedleg members406 are shown without leg modules, and the fenestrations are shown with a circular shape. As noted before, the plurality of encapsulatedleg members406 may be formed with or without leg modules. Thefluid delivery subsystem445 allows various fluids, such as medicines or irrigation fluids, to be delivered into the cavity. The delivered fluids may then be removed by the open-cavity, reduced-pressure treatment device402. Thefluid delivery subsystem445 includes a central port447, which may be placed on or in a central connection member412, for connecting to a conduit (not shown) that delivers the fluid from a location external to the central port447. Fluidly coupled to the central port447 is a plurality of fluid-delivery conduits449. The plurality of fluid-delivery conduits449 may be located anywhere on anon-adherent drape448, but in this illustrative embodiment, are disposed in the plurality of encapsulatedleg members406. The plurality of fluid-delivery conduits449 are opened on theirdistal ends451 to allow the delivery of fluid therethrough. The flow of fluid through the distal ends451 of the plurality of fluid-delivery conduits449 is suggested byarrows453.

In use, the open-cavity, reduced-pressure treatment device402 may be used in a fashion analogous to that of thetreatment devices102 and302, but at various times or even continuously, it may be desirable to deliver a fluid through thefluid delivery subsystem445. For example, it may be desirable to flush the abdominal cavity with an irrigation fluid or to deliver periodic doses of medicine.

Another illustrative embodiment for using an open-cavity, reduced-pressure treatment device (e.g., cavity, reduced-pressure treatment device102,302,402) or system will now be presented. The system is particularly suitable for temporary bridging of abdominal wall openings where primary closure may not be readily possible and or repeat abdominal entries are necessary. The illustrative system described here may be used with open abdominal wounds, with exposed viscera, including but not limited to abdominal compartment syndrome. Before applying the system, typically hemostasis should be achieved.

In deploying the open-cavity, reduced-pressure treatment system, the reduced-pressure treatment device preferably covers all exposed viscera and preferably separates completely the viscera from contact with the abdominal wall. For example, the lower surface of the reduced pressure treatment device, such asdrape148, can be sized and shaped to permit coverage. The reduced-pressure treatment device may be placed over the omentum or exposed internal organs, and carefully tucked between the abdominal wall and internal organs. In doing so, the healthcare provider may use the reduced-pressure treatment device to completely separate the abdominal wall from the internal organs.

To prepare for deployment of the system, any sharp edges or bone fragments are eliminated from wound area or covered. The abdominal wound is irrigated and the periwound area cleaned. The periwound tissue at the epidermis is typically dried before further application.

The reduced-pressure treatment device is then sized by determining the appropriate size and cutting. The reduced-pressure treatment device is initially unfolded in a sterile field. Either side of the reduced-pressure treatment device may be placed on the omentum or viscera. The reduced-pressure treatment device is gently placed over the open abdominal cavity. The orientation of the reduced-pressure treatment device for the specific application is determined. If the reduced-pressure treatment device will be placed around tubes, drains or the falciform ligament, the reduced-pressure device is cut only between the plurality of encapsulated leg members. The reduced-pressure treatment device is placed in the proper orientation before cutting.

The reduced-pressure treatment device is then folded to size and used that way or may be cut. The healthcare provider holds the reduced-pressure treatment device by the edge and slightly lifts the reduced-pressure treatment device. The reduced-pressure treatment device is slowly lowered into the paracolic gutter with one hand and the other hand is used to gently and evenly work the reduced-pressure treatment device down. The healthcare provider folds any excess portions of the reduced-pressure treatment device up and over onto itself. The healthcare provider continues to place the reduced-pressure treatment device between abdominal wall and internal organs throughout the abdominal compartment. The healthcare provider preferably provides full coverage of all viscera. The reduced-pressure treatment device may then be cut as needed for sizing outside of the wound.

To size the device, the reduced-pressure treatment device can be cut through center of one of the large manifold squares, or leg modules, using sterile scissors. In this illustrative embodiment, the cut is not made through the manipulation zone, but through the leg module. The healthcare provider then pinches the remaining half of the foam square, or leg module, and the adjacent, inboard manipulation zone through the encapsulating member with one hand and pulls the manifold material. The manifold material in the leg module and the manipulation zone will separate at the next square, or leg module. This will ensure that edges of the reduced-pressure treatment device cover the otherwise exposed manifold edge. The manifold material, e.g., foam, preferably does not contact organs.

The manifold that is to be placed on top of the central connection member is next prepared. In this embodiment, the manifold may be a perforated foam manifold that has perforations to help tear the manifold to the desired size. The manifold preferably fits directly over the reduced-pressure treatment device while still being in contact with wound edges. The manifold should not contact intact skin. Two or more manifolds may be used in some instances. Then, the sized manifold is gently placed into the wound cavity over the reduced-pressure treatment device. The healthcare provider preferably takes care to avoid the manifold going below the level of the abdominal incision or wound.

A drape, or over-drape, is then applied. To apply the drape, a backing is removed from an adhesive layer on one side of the drape and the drape is applied. The drape covers the manifold and a portion of intact epidermis. Preferably the drape covers at least an 8-10 centimeter border of intact periwound tissue. Additional drape material may be added to seal any difficult areas.

The reduced-pressure interface, or interface pad, is then added. The healthcare provider chooses an application site. The site is chosen to optimize fluid flow as well as to facilitate easy tubing positioning. The healthcare provider pinches the drape and cuts a 2.5 cm hole (preferably not a slit) through the drape. The interface pad, which has a central disc and a surrounding outer adhesive skirt, is applied. The interface pad is applied by removing backing layers on an inward-facing surface of the interface pad to expose an adhesive. The interface pad opening in the central disc is placed directly over the hole in the drape. Pressure is gently applied on the central disc and the outer skirt to ensure complete adhesion of the interface pad. One or more stabilization layers may then be removed from a first side of the skirt. The system is now ready for the application of reduced pressure.

According to another illustrative embodiment, which is shown inFIG. 5, an open-cavity, reduced-pressure treatment device502 includes acentral fluid hub512 and a plurality ofelongate members506. Thecentral fluid hub512 has anupper surface513 and a lower surface. Thecentral fluid hub512 includes afoam manifold554, which defines at least a portion of theupper surface513, and a substantially fluid impermeable wall, which defines at least a portion of the lower surface. The fluid impermeable wall includes a plurality ofapertures518. The plurality ofelongate members506 have aproximal end515,distal end517, and upper519 and lower surfaces. Theelongate members506 include a foam enclosed within substantially fluid impermeable walls. The proximal ends515 of the plurality ofelongate members506 are in fluid communication with thecentral fluid hub512. Theelongate members506 includeapertures514 extending through the fluid impermeable wall along at least a portion of the lower surface of theelongate members506.

The plurality ofelongate members506 have a first length L1 extending from thecentral fluid hub512 and a first width (W₁) generally parallel to the upper surface and perpendicular to the first length. The central hub has a second width (W₂) between lateral edges on a portion between a first and second elongate member. The second width is greater than the first width (W₂>W₁). The plurality ofelongate members506 are fluidly coupled to thecentral hub512. The open-cavity, reduced-pressure treatment device502 may have an aspect ratio of the plurality ofelongate members506 in the range of 3.0 to 10.0. The open-cavity, reduced-pressure treatment device502 may have an aspect ratio of the plurality ofelongate members506 that is greater than 3.5. The open-cavity, reduced-pressure treatment device502 may also include anelastic material585 extending between the plurality ofelongate members506.

Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in a connection to any one embodiment may also be applicable to any other embodiment.

Claims (14)

We claim:

1. A treatment device, comprising:

a central fluid hub having an upper surface and a lower surface, the fluid hub including a foam manifold defining at least a portion of the upper surface and a substantially fluid impermeable wall defining at least a portion of the lower surface, the fluid impermeable wall including a plurality of apertures; and

a plurality of elongate members having a proximal end, a distal end, an upper surface, and a lower surface, the elongate members including a foam enclosed within a substantially fluid impermeable wall material, the proximal ends of the plurality of elongate members in fluid communication with the central fluid hub, the elongate members including apertures extending through the substantially fluid impermeable wall material along at least a portion of the lower surface of the elongate members.

2. The treatment device ofclaim 1, wherein:

the plurality of elongate members have a length extending from the central fluid hub and a first width generally parallel to the upper surface;

the central fluid hub has a second width between a first elongate member and a second elongate member;

the second width is greater than the first width; and

an aspect ratio of the plurality of elongate members is in the range of 3.0 to 10.0.

3. The treatment device ofclaim 1, wherein:

the plurality of elongate members have a length extending from the central fluid hub and a first width generally parallel to the upper surface;

the central fluid hub has a second width between a first elongate member and a second elongate member;

the second width is greater than the first width; and

an aspect ratio of the plurality of elongate members is greater than 3.5.

4. The treatment device ofclaim 1, further comprising a substantially fluid impermeable material extending between the plurality of elongate members.

5. The treatment device ofclaim 1, further comprising an expandable material extending between the plurality of elongate members.

6. The treatment device ofclaim 1, wherein the central fluid hub and the plurality of elongate fluid members are configured to be disposed adjacent to a tissue site.

7. The treatment device ofclaim 1, wherein the lower surface of the plurality of elongate members is configured to substantially contact a tissue site along a length of the elongate member.

8. A treatment device, comprising:

a fluid hub including an upper surface, a lower surface, a foam manifold, and a substantially fluid impermeable wall defining at least a portion of the lower surface, the fluid impermeable wall including a plurality of apertures; and

a plurality of elongate members including an upper surface, a lower surface, and a foam enclosed within a substantially fluid impermeable wall material, the plurality of elongate members in fluid communication with the fluid hub and including apertures extending through the substantially fluid impermeable wall material along at least a portion of the lower surface of the elongate members;

wherein the lower surface of the plurality of elongate members is configured to substantially contact a tissue site along a length of the elongate member.

9. The treatment device ofclaim 8, wherein:

the plurality of elongate members have a length extending from the fluid hub and a first width generally parallel to the upper surface;

the fluid hub has a second width between a first elongate member and a second elongate member;

the second width is greater than the first width; and

an aspect ratio of the plurality of elongate members is in the range of 3.0 to 10.0.

10. The treatment device ofclaim 8, wherein:

the plurality of elongate members have a length extending from the fluid hub and a first width generally parallel to the upper surface;

the fluid hub has a second width between a first elongate member and a second elongate member;

the second width is greater than the first width; and

an aspect ratio of the plurality of elongate members is greater than 3.5.

11. The treatment device ofclaim 8, further comprising a substantially fluid impermeable material extending between the plurality of elongate members.

12. The treatment device ofclaim 8, further comprising an expandable material extending between the plurality of elongate members.

13. The treatment device ofclaim 8, wherein the fluid hub and the plurality of elongate fluid members are configured to be disposed adjacent to a tissue site.

14. The treatment device ofclaim 8, wherein the foam manifold defines at least a portion of the upper surface of the fluid hub.

Images